Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28553590 | 0.91 | MAPT (0.59) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL10643494 | 0.89 | GAA (0.58) | MAPTGAAALDH1A1PTGS2LMNA | |
| SCHEMBL21157727 | 0.86 | GAA (0.57) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL21157751 | 0.86 | GAA (0.57) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL1496777 | 0.86 | GAA (0.63) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL8605149 | 0.86 | GAA (0.56) | MAPTGAAALDH1A1PTGS2LMNA | |
| SCHEMBL27183219 | 0.86 | GAA (0.56) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL20766578 | 0.85 | MAPT (0.60) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL21156443 | 0.85 | GAA (0.56) | MAPTGAAALDH1A1PTGS2MEN1 | |
| SCHEMBL21156916 | 0.85 | GAA (0.56) | MAPTGAAALDH1A1PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | claimed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | claimed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | claimed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2020207611-A1 | PHENAZINES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS 2 (DDR2) | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020207570-A1 | PHENAZINES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS 2 (DDR2) | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-10-15 | — | — | WO | disclosed |
| WO-2017129818-A1 | LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2017-08-03 | — | — | WO | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2013149997-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | disclosed |
| EP-2647628-A1 | Substituted tricyclic compounds with activity towards ep1 receptors | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | disclosed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0582506-B1 | Tetrahydronaphtalene derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1996-02-28 | — | — | EP | disclosed |
| US-5373023-A | Antiischaemic agent | SYNTHELABO (FR) | 1994-12-13 | — | — | US | disclosed |
| EP-0582506-A1 | Tetrahydronaphtalene derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069262-A1 | Oxadiazoles and their manufacture | OXA1L, CYP1B1, OXER1 | MAPT 2422/4885GAA 3856/4885ALDH1A1 331/4885 |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | KCNH1, KCNJ2, KCNH2 | MAPT 4219/4885GAA 3593/4885ALDH1A1 715/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MAPT 3239/4885GAA 211/4885ALDH1A1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.